StemData relaunch

Global Stem Cells Group has announced the relaunch of its StemData cloud-based electronic medical record system specifically designed for regenerative medicine practitioners.

MIAMI, Nov. 29, 2017—Global Stem Cells Group, a world leader in stem cell and regenerative medicine, has announced the relaunch of its StemData software, the first cloud-based electronic medical record system specifically designed for regenerative medicine practitioners.

The StemData system, initially launched in September 2016, is a customized software program for physicians who operate a regenerative medicine practice. The StemData software empowers physicians to follow patients throughout their treatment schedules. The StemData program comes programmed with the latest point-of-care regenerative medicine protocols and follow-up procedures to make it easy for stem cell patients to schedule appointments by phone, and for practitioners to document patient progress and gather important data to establish the safety and efficacy of stem cell treatments in the physician’s office environment.

The StemData system app is marketed exclusively through Global Stem Cells Group and will be provided free of charge to affiliate physicians in the Stem Cell Center network.

StemData’s cloud-based, server-less solution is accessible via web, iPad, iPhone, Google Glass and Apple Watch. Global Stem Cells Group has utilized the development of the latest electronic medical record (EMR) systems to bring intelligent EMR technology to regenerative medicine specialists.

The StemData app helps regenerative medicine practitioners increase efficiencies in their medical practices while improving both treatment and business outcomes. The app will intuitively adapt to each individual practitioner’s unique practice preferences.

To learn more about GSCG’s StemData solution, visit http://www.stemdata.org, email info@stemcellsgroup.com, or call +1305 560 5337.

About Global Stem Cells Group:

stemdata relaunch


Global Stem Cells Group
(GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell Group’s aim is to be the largest recognized stem cell and regenerative medicine network in the world.

stemdata relaunch

ISSCA Buenos Aires

The International Association for Stem Cell Application moved to a new office at Piedra 383 at Ciudad Autonoma of Buenos Aires, Argentina. The move accommodates ISSCA’s increasing specialty and patient volume, as well as its expanding regenerative medicine certification training programs.

MIAMI, Nov. 29, 2017—The International Association for Stem Cell Application (ISSCA) has announced the move of its Puerto Madero office in Buenos Aires to a new location just a few blocks away to Piedra 363. The new location will house an ISSCA regional office and treatment center.

ISSCA Buenos Aires

The move to the larger office reflects ISSCA’s need to accommodate rapidly expanding patient volume and specialty offerings at its Buenos Aires center. The larger clinical and office space will allow ISSCA to continue providing superior services to patients traveling from the U.S, and worldwide for regenerative medicine treatments. The new location includes a dedicated conference room to host ongoing regenerative medicine training programs and more than three new procedure rooms.

ISSCA celebrated the new location’s grand opening Nov. 26-27, 2017, and host ISSCA regenerative medicine certification training courses for physicians.

To learn more about the ISSCA’s Buenos Aires center and training courses, visit the ISSCA website, email info@stemcellsgroup.com, or call 305-560-5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

###

ISSCA Buenos Aires

Magellan Autologous

                                                                            Magellan Autologous Platelet Separator

Global Stem Cells Group and its subsidiary Adimarket named representatives for Magellan Autologous Platelet Separator in Latin America and Middle East.

 MIAMI, Nov. 29, 2017— Global Stem Cells Group (GSCG), a world leader in stem cell and regenerative medicine, and its subsidiary Adimarket have been named to represent the Magellan Autologous Platelet Separator in Latin America and Middle East.

Developed by Arteriorcyte Medical Systems, a leading medical device company headquartered in Hopkinton, Mass., the Magellan Autologous Platelet Separator is a high-tech, automated dual spin processing system designed for use in clinical laboratories or intraoperatively at the point-of-care for safe and rapid preparation of high-quality, platelet-rich plasma (PRP) as well as platelet poor plasma (PPP).

Global Stem Cells Group CEO Benito Novas says the Magellan system is a perfect fit for GSCG and Adimarket’s ever-growing list of high-tech regenerative medicine products and equipment, made available to physicians and qualified practitioners through the Adimarket online store.

“We share Arteriocyte’s commitment to research and development of blood component technology to advance treatments that benefit patients in the field of regenerative medicine,” Novas says. “The Magellan system furthers GSCG’s drive to invest in platelet separation technologies that focus on the development of new surgical applications for PRP and elevates these technologies to the next level.”

The fully-automated Magellan system is specifically designed to fractionate blood at bedside without a need for manual manipulation. At the end of its cycle, the Magellan PRP is delivered into a collection syringe, ready for immediate application.

As an industry leader, Adimarket added the Magellan Autologous Platelet Separator System to its online regenerative medicine store to allow physicians to meet the specific needs of each patient with fully customizable product volumes and platelet concentrations. The system can be programmed to deliver a volume of 3 – 10 mL from each processing cycle, allowing practitioners to customize the concentration per mL within the PRP.  The Magellan system is approved for three processing cycles per disposable separation chamber, allowing for a maximum of 30 mL of product.

For more information, visit the Adimarket regenerative medicine online store website, email info@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

About Adimarket:

Adimarket, Inc., a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.

Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.

About Arteriorcyte Medical Systems:
Magellan Autologous Platelet Separator
Arteriocyte Medical Systems, Inc. is a leading medical device company committed to developing and marketing novel medical products to help patients heal faster. Established in 2007 by Arteriocyte, Inc. and DW Healthcare Partners, Arteriocyte Medical Systems is devoted to providing innovative solutions to patients and medical professionals to address serious unmet medical needs particularly in cardiac, orthopedic and vascular surgeries.

###

Magellan Autologous platelet separator

ISSCA Miami

ISSCA will conduct the first regenerative medicine certification training course for the upcoming year in Miami Feb. 2-3, 2018. The two-day course focuses on pain management and aesthetic regenerative medicine protocols.

MIAMI, Nov. 20, 2017—The International Society for Stem Cell Application (ISSCA) announced plans to hold its first regenerative medicine certification training course of the upcoming year Feb. 2 – 3, 2018 in Miami.

The two-day, hands-on training course focuses on pain management and aesthetic regenerative medicine protocols. Practitioners learn skills that can be used to treat patients in their practices, and for career advancement. The course provides participating physicians with training in stem cell applications to benefit patients undergoing aesthetic procedures or being treated for specific medical condtions.

Participating physicians will also receive access to the online stem cell training course to review all content and procedures introduced in the 2-day clinical training course, patient forms and guidelines, procedure informed consent forms, didactic lectures, training booklets, and more.

The ISSCA pain management and aesthetic regenerative medicine protocols training course was developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells derived from adipose tissue and bone marrow.

Stem cell therapies continue to revolutionize the anti-aging aesthetics industry and help improve the quality of life for patients suffering from some chronic conditions.

To learn more about the training course and register to participate, visit the Stem Cell Training Course website, email info@stemcellsgroup.com, or call 305-560-5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

 

Cidranes ISSCA

 

Ernesto Miguel Delgado Cidranes, M.D., Ph.D., appointed regional director of ISSCA chapter in Europe.

MIAMI, Nov. 22, 2017—International Society for Stem Cell Application (ISSCA) President Daeyong Kim, Ph.D., has named Ernesto Miguel Delgado Cidranes, M.D., Ph.D., Regional Director of the ISSCA chapter in Europe.

Cidranes is an anesthesiologist and resuscitation and intensive care specialist in, Madrid, Spain. He is a renowned expert in pain management and promotes an integrative and interdisciplinary approach to the treatment of pain. Cidranes’s areas of expertise include interventional pain management, pain treatment, stem cell therapies, and regenerative medicine.

As the European regional director, Cidranes will promote ISSCA activities in EU, and collaborate with the organization to establish new standards for regenerative medicine protocols worldwide. Cidranes will conduct a specialized training workshop in pain management and cosmetic gynecology Feb. 25-26, 2018 in Madrid, Spain, and plans to promote the workshop throughout Europe.

He is director, CEO, and founder at Advanced Pain and Aesthetic Management Center in Madrid, and serves on the advisory board for ISSCA affiliate Global Stem Cells Group. Cidranes is also head of service at the La Milagrosa Hospital Pain Unit and the Pain Unit Los Madronas Hospital, both in Madrid.

He serves as a medical specialist in anesthesiology-reanimation and pain therapy at the Hospital Ramon y Cajal in Madrid, and an editorial board member of the Journal Pain Management and Therapy. Cidranes is also a popular international speaker on pain management, stem cell therapies, regenerative medicine, and ultrasound techniques.

“It is a pleasure to have Dr. Cidranes representing ISSCA in Europe, and as a collaborator in our efforts to establish new regenerative medicine standards worldwide,” He brings a wealth of experience and expertise to the ISSCA organization.”

To learn more about ISSCA, visit the stemcellglobal.org website, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

 

human stem cells

Scientists from the U.K. and Sweden have discovered a new method of creating human stem cells that could solve the problem of meeting large-scale production needs, allowing researchers to fully realize the potential of stem cells for understanding and treating disease.

Human pluripotent stem cells are undifferentiated cells that have the unique potential to develop into all the different types of
cells in the body. With applications in disease modeling, drug screening, regenerative medicine and tissue engineering, there is already an enormous demand for these cells, and that demand will continue grow as their use in clinical settings and the pharmaceutical industry increases.

Human embryonic stem cell line HUES1 grown in the new conditions E8+Inter-alpha-inhibitor and imaged for stem cell marker Oct4 (green) and cell-cell attachment molecule E-cadherin (red) with nuclear counter-staining (blue). Credit: Dr. Sara Pijuan-Galito and Dr. Cathy Merry, Wolfson Centre for Stem Cells, Tissue Engineering & Modelling and Centre for Biomolecular Sciences, The University of Nottingham Read more at: http://phys.org/news/2016-07-breakthrough-scaling-life-changing-stem-cell_line

Human embryonic stem cell line HUES1 grown in the new conditions E8+Inter-alpha-inhibitor and imaged for stem cell marker Oct4 (green) and cell-cell attachment molecule E-cadherin (red) with nuclear counter-staining (blue).
Credit: Dr. Sara Pijuan-Galito and Dr. Cathy Merry, Wolfson Centre for Stem Cells, Tissue Engineering & Modelling and Centre for Biomolecular Sciences, The University of Nottingham.

However, production of stem cells at the scale required for optimal application in modern research and healthcare has not beenfeasible because available culture methods are either too expensive, or reliant on substances that would not be safe for clinical use in humans.

The research results, published in Nature Communications in July, describe how the scientific team from The University of Nottingham’s Wolfson Centre for Stem Cells, Tissue Engineering and Modelling at Uppsala University in Sweden and GE Healthcare also in Sweden have identified and improved human stem cell culture methods that could lead to quicker and cheaper large scale industrial production of human pluripotent stem cells.

By using a protein derived from human blood called Inter-alpha inhibitor, the team has grown human pluripotent stem cells in a minimal medium without the need for costly and time-consuming biological substrates. Inter-alpha inhibitor is found in human blood at high concentrations, and is currently a by-product of standard drug purification schemes.

The human serum-derived protein can make stem cells attach to unmodified tissue culture plastic, eliminating the need for coating in defined human pluripotent stem cell culture, and improving survival capabilities of the stem cells in harsh conditions.

It is the first stem cell culture method that does not require a pre-treated biological substrate for attachment, and therefore, is more cost and time efficient, paving the way for easier and cheaper large-scale production.

Existing methods are time consuming and make developing human stem cell cultures prohibitively costly. This new method has the potential to save time and money in large-scale and high-throughput cultures, and be highly valuable for both basic research and commercial applications.

The work began at Uppsala University, and the study’s first author, Sara Pijuan-Galitó PhD., is continuing her work as a Swedish Research Council Research Fellow at Nottingham.

Researchers now intend to combine Inter-alpha inhibitor protein with an innovative hydrogel technology to improve on current methods for controlling cell differentiation, and also apply it to disease modelling. The discovery, according to the findings, will help facilitate research into many diseases although their focus is currently on understanding rare conditions like Multiple Osteochondroma) at the cellular level. The aim is to replicate the 3 dimensional environment that cells experience within the body so that lab-bench biology is more accurate in modelling diseases.

Pijuan-Galitó has been awarded the Sir Henry Wellcome Postdoctoral Fellowship at Nottingham University for her work on the research, which will enable her to combine Inter-alpha inhibitor with improved synthetic polymers in collaboration with fellow regenerative medicine pioneers Professor Morgan Alexander and Professor Chris Denning. The team plans to further improve on current human stem cell culture by designing an economical and safe method that can be easily translated to large-scale production and can deliver billions of stem cells necessary move cellular therapeutics forward in patient settings.

The study, titled “Human serum-derived protein removes the need for coating in defined human pluripotent stem cell culture,” was published in Nature Communications in July, 2016.

###

stem cell training certification

MIAMI, Sept. 13, 2016-Global Stem Cells Group announced plans to hold a stem cell training certification course Oct. 1 -2, 2016 following the 3rd annual Global Stem Cells Group International Symposium on Stem Cells and Regenerative Medicine in Buenos Aires. The symposium will take place Sept. 28, 2016.

The two-day, hands-on training course covers the latest technology and procedures in SVF and bone marrow stem cell techniques. Practitioners learn skills that can be used to treat patients in their practices, and for career advancement. The SVF and bone marrow aspiration course was developed for physicians and high-level practitioners to learn techniques in harvesting and rein

stem cell training certification

Joseph Purita, MD

tegrating stem cells derived from adipose tissue and bone marrow. The objective of the training teach effective, in-office regenerative medicine techniques.

stem cell training certification

Silvina Pastrana, M.D.

The course will be taught by GSCG Advisory Board members Joseph Purita, M.D. and Silvina Pastrana, M.D.

The stem cell training certification course will be held at the Global Subsidiary Stem Cell Center Network in Puerto Madero Buenos Aires immediately following the 3rd annual International Symposium on Stem Cells and Regenerative Medicine.

Since 2014, Global Stem Cells Group has joined forces with some of the most prestigious regenerative medicine practitioners in South America as it focuses on growing its services throughout the global community. Stem cell therapies continue to revolutionize the anti-aging aesthetics industry and help improve the quality of life for patients suffering from some chronic conditions.

To learn more about the 3rd Annual International Symposium on Stem Cells and Regenerative Medicine, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.
stem cell training certification
About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

To view this press release live online, click here

###

Panama Congress

MIAMI, Sept. 9, 2016—Global Stem Cells Group will attend the Colombian Association of  Sports Medicine’s First Latin American Congress on Sports Medicine, Injuries, Treatment and Rehabilitation in Panama City, Panama Sept. 22 – 24, 2016. The Panama Congress will focus on a variety of Sports Medicine specialties presented in an academic activity framework.

The congress will host a diverse range of esteemed guests, including physicians, athletes, athletic coaches, physical therapists, medical exercise physiologists, orthopedists, physical medicine and rehabilitation (PM&R) physicians (physiatrists), Paralympics athletes, endocrinologists, diabetologists, orthopedic surgeons, internists, physical educators, pain specialists, nutrition and dietetic specialists, psychologists, neuro surgeons and neuro rehabilitation specialists.

The event, to be hosted at the Hotel Riu Plaza in the heart of Panama City’s financial district, will provide a dynamic atmosphere showcasing local, national, international and Latin American ambience.

To learn more about the First Latin American Congress on Sports Medicine, visit the event website.To learn more about Global Stem Cells Group, visit the GSCG website, email bnovas(at)stemellsgroup.com, or call 305-560-5337.

Panama Congress

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

To review this press release live online, click here

###

Speakers Buenos Aires

MIAMI, Sept. 9, 2016—Global Stem Cells Group has announced its lineup of speakers for the 3rd Annual International Symposium on Stem Cells and Regenerative Medicine, to be held Sept. 28, 2016 in Buenos Aires, Argentina. In keeping with tradition, the symposium will be hosted by GSCG in collaboration with Julio Ferreira, M.D., President of the South American Academy Cosmetic Surgery.

The symposium will be a gathering of many of the world’s most respected authorities on stem cell and regenerative medicine, who will share the latest findings and showcase advancements in research and therapies on a global level. The interdisciplinary team of leading international stem cell experts will provide a full day of high-level scientific lectures geared to medical professionals. Pioneers and luminaries in stem cell medicine who will serve as featured speakers at the event include:

Joseph Purita, M.D.

Joseph Purita, M.D., USA
Musculoskeletal and antiaging applications of stem cells.
Joseph Purita, M.D., is an internationally recognized orthopedic surgeon and pioneer in the application of stem cells and PRP therapies for orthopedic injuries and diseases. Dr. Purita pioneered laser techniques in orthopedic surgery, and specializes in the treatment of high-performance athletes. Dr. Purita is a member of the Global Stem Cells Group Advisory Board.

Buenos Aires Stem Cell SymposiumEnrique Testart,, M.D., Chile
Osteogenesis and the future of heterologous implants.
Enrique Testart, M.D., is a pediatric surgeon specializing in child trauma microsurgery. Dr. Testart has developed distinctive techniques and protocols in cellular therapies and management protocols for musculoskeletal disorders. He has dedicated years to researching and practicing techniques that employ stem cell therapies to enhance conventional surgical techniques to ease patient suffering. Dr. Testart is Global Stem Cells Group’s Chile Representative

Rafael Perez Franco, M.D.Rafael Pérez Franco, M.D., Colombia
Use of cell therapy in the treatment of alopecia.
Rafael Perez Franco, M.D. is director of the Rafael Perez Center for Reconstructive and Aesthetic Surgery in Bogota, Colombia. An expert in his field for more than 10 years, Dr. Perez Franco is a surgeon at the Universidad del Bosque and a plastic surgeon at the Clínica San Rafael in Colombia. Dr. Perez Franco also holds special rotations at Hospital Saint Paul in San Pablo, Brazil and the Clínica Fluminense de Cirugía Plástica and Clínica del Profesor Ivo Pitanguy in Rio de Janeiro. He is a member of the Global Stem Cells Group Advisory Board.

Carlos Chirigoba Assini, M.D.Carlos Chiriboga Assini, M.D., Ecuador
Application of Neural therapy and stem cell therapy in the treatment of injuries for high performance athletes.
Carlos Chirigoba Assini, M.D. serves as Chairman of the Board ar Omnihospital Medical Association in Guayaquil, Ecuador. Dt. Chirigoba Assini specializes in traumatology, orthopedic surgery, and platelet rich plasma (PRP) therapies. He is a member of Omnihospital Medical Association and the American Academy of Antiaging.

Aldo Parodi, M.D.Aldo Parodi, M.D. Perú
Aesthetic applications of cellular therapies.
Aldo Parodi, M.D. is a plastic surgeon and laser liposuction specialist with clinical experience in assisted lipotransference. Dr. Parodi offers aesthetic treatments using adipose-derived stem cells at his aesthetic medicine clinic Clinic La Femme in Tacna, Peru. He is a member of the Global Stem Cells Group Advisory Board.

Silvina Pastrana, M.DSilvina Pastrana, M.D. Argentina.
Implementation of cellular therapies. Presentation of clinical cases.
Silvina Pastrana, M.D. is a surgeon and medical director of the Stem Cell Center Buenos Aires and Regentherapy Puerto Madero. Dr. Pastrana heads a staff of medical specialists in orthopedics, rheumatology, medical clinic and cosmetic surgery, performing procedures incorporating stem cell therapies. She also serves as a staff surgeon for the Hospital Dr. Prof. Luis Güemes, and is a member of the Global Stem Cells Group Advisory Board.

benito2Benito Novas, CEO, Global Stem Cell Group, United States
Developments and Challenges of Regenerative medicine globally.
Benito Novas, founder, CEO and creative director of Global Stem Cells Group, Mr. Novas also spearheaded and launched Stem Cell Training Inc. to provide professional training courses in stem cell therapies for physicians. Mr. Novas oversees Stem Cell Training marketing programs, finance strategies, field operations administration, policies, procedures and accreditation. Prior to founding The Global Stem Cells Group, Mr. Novas was President and CEO of Adimarket, Inc.

Leonardo Tacus, M.D.Leonardo Tacus, M.D. Argentina
Muscle and tendon injuries in regenerative medicine.
Leonardo Tacus, M.D. is an arthroscopic surgeon specializing in orthopedics, traumatology, and regenerative medicine. Dr. Tacus is the medical director at iar sa Argentina Hospital and Health Care, and co-director of Education Center Graduate Medical Surgery, orthopedics and Trauma (CECOA) in Buenos Aires. He is a founding member of the Argentina Association of Arthroscopy and past secretary of the Argentina Association of Arthroscopy

Daniel DominguezDaniel Domínguez, Aregntina
Systematics in the preparation of blood components for Regenerative Medicine.
Daniel Domínguez is the operations manager of High Technology Systems S.A. in Buenos Aires. Mr. Dominguez’s background includes hemotherapy and laboratory tech.

Susana Miriam Gjurkan, D.M.D. Argentina Susana Miriam Gjurkan, D.M.D. Argentina
Application of stem cells and PRP in temporomandibular joint ATM (modified technique)
Susana Miriam Gjurkan, D.M.D., is a surgical specialist in orthodontics, cosmetic dentistry, dental implants, preventive dentistry, pediatric dentistry, periodontics, prosthetic dentistry, neurofacial and aesthetic dentistry. She uses stem cells and PRP to treat temporomandibular joint (TMJ) disorders in patients (modified technique). Dr. Gjurkan operates from her clinic, ONE Surgery, in San Miguel de Tucuman, Argentina. She has attended and taught courses in neural therapy, and earned her stem cell certification through Stem Cell Training.

Since 2014, Global Stem Cells Group has joined forces with some of the most prestigious regenerative medicine practitioners in South America as it focuses on growing its services throughout the global community. Stem cell therapies continue to revolutionize the anti-aging aesthetics industry while offering new hope for sufferers of serious chronic debilitating diseases.

To learn more about the 3rd Annual International Symposium on Stem Cells and Regenerative Medicine, visit the Global Stem Cells Group website,email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

About Julio Ferreira, M.D.

Julio Ferreira advisory board, Global Stem Cells Group

Julio Ferreira, M.D., President of the South American Academy of Cosmetic Surgery, is a professor at the Institute of Biomedical Sciences, University of Sao Paulo, Brazil. In addition, he is the former President of the International Academy of Cosmetic Surgery 2005/2007; a member and examiner, International Board of Cosmetic Surgery; Corresponding Fellow of the American Academy of Cosmetic Surgery; Honorary Member of the Spanish Society of Cosmetic Medicine and Surgery; Honorary Member of the Eurorusa Confederation of Societies of Aesthetic Plastic Surgery; Honorary Member of the Bulgarian Society of Cosmetic Surgery; Honorary Member of the Chilean Society of Cosmetic Surgery and Lipoplasty; Honorary Member of the Italian Society of Aesthetic Surgery; Honorary Member of the French Society of Aesthetic Surgery; Honorary Member of the Japan Society of Aesthetic Surgery; Honorary Member of the Ecuadorian Society of Medical Aesthetics; Honorary Member of the Peruvian Society of Cosmetic Surgery, and a member of the International Editorial Advisory Board of the American Journal of Cosmetic Surgery.

To view this press release live online, click here

###

closed system kit

MIAMI, Sept.8, 2016—Adimarket, a subsidiary of Global Stem Cells Group, Inc., has announced that Korean biotech leader N-Biotek is developing a new closed system kit containing all of the elements necessary to process adipose tissue and obtain stromal vascular fraction (SVF) in a closed environment.

Created with N-Biotek technology, the system will allow entire procedures to be performed in a sterile closed system.
Adipose derived stem cells (ASCs) are used by physicians for a variety of indications.

Most commonly, ASCs are isolated at the point of care from lipoaspirate (derived from liposuction) tissue as the stromal vascular fraction (SVF), harvested from the patient and immediately administered to the patient as an injection, or used to enrich fat grafts. Isolation of ASCs from adipose tissue is a relatively simple process performed routinely in cell biology laboratories, but isolation at the point of care for immediate clinical administration requires special methodology to prevent contamination, ensure integrity of the clinical procedure, and comply with regulatory requirements.

Once available on the Adimarket product website, the N-Biotek kit can provide a low cost, rapid and simple alternative to traditional methods of isolating ASCs, particularly when smaller quantities are needed.

To learn more about the N-Biotek closed system kit, visit the Adimarket website or the Global Stem Cells website, email bnovas@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell closed system kit N-Biotekresearch, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About Adimarket:

Adimarket, Inc., a division of the Global Stem Cells Group, is a cost-competitive online marketplace for quality regenerative medicine equipmCloN-Bioteksed system kit ent and supplies for physicians and health care professionals. Adimarket
was founded to provide physicians and other health care professionals the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact the practice of stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting edge treatments.

Adimarket’s experienced customer service representatives provide valuable guidance and advice regarding products relevant to individual practices.

About N-Biotek:

stem cell training KoreaSince 1982, N-Biotek has been the leading manufacturer of biomedical and lab equipment worldwide. The Stem Cell Total Solution lab is a culmination of years of dedication to establish compact and customized products in developing the Handy Lab, a personal lab for medical, scientific and university professionals. N-Biotek is known for its high quality, uniquely designed biomedical products and equipment and competitive pricing. Over the years, the company’s products have earned an array of patents, and all meet international standards including CE, ETL, ISO and GMP. N-Biotek also offers real-time monitoring through IT technology.

Since 2010, N-Biotek has expanded significantly, starting new businesses including a stem cell processing system and biological clean room, GMP consulting, validation services and health care services for foreign consumers in order to maintain its lead in the life science field.
To view this press release live online, click here

###